Market Cap (In SEK)
297.92 Million
Revenue (In SEK)
-
Net Income (In SEK)
-109.28 Million
Avg. Volume
428.62 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.888589-17.98
- PE
- -
- EPS
- -
- Beta Value
- 1.031
- ISIN
- SE0010573113
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Magnus O. Corfitzen
- Employee Count
- -
- Website
- https://www.ascelia.com
- Ipo Date
- 2019-03-13
- Details
- Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
More Stocks
-
3E2Etsy, Inc.
3E2
-
SENA
-
000957
-
MATRIMONYMatrimony.com Limited
MATRIMONY
-
BCOW
-
OWUV
-
0639
-
GUNKUL